{"schema_version":"secwatch.filing_event.v1","accession":"0001178913-25-001909","form_type":"8-K","ticker":"SLXN","cik":"0002022416","company_name":"Silexion Therapeutics Corp","filed_at":"2025-05-21T23:59:59+00:00","discovered_at":"2026-05-14T18:02:50.696954+00:00","generated_at":"2026-05-20T22:59:36.330205+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Silexion Therapeutics completes preclinical studies of SIL204 in KRAS-driven colorectal, lung, and pancreatic cancers","bullets":["SIL204 evaluated in GP2D (colorectal), A427 (lung), and Panc-1 (pancreatic) KRAS-mutant cell lines.","Company expects to announce comprehensive results within the next few days.","If positive, SIL204 could expand development strategy beyond pancreatic cancer.","Global treatment markets for these three KRAS-driven cancers estimated at over $30 billion annually.","KRAS mutations drive ~90% of pancreatic, ~45% of colorectal, and ~35% of non-squamous NSCLC."],"urls":{"canonical":"https://secwatch.observer/filing/0001178913-25-001909","json":"https://secwatch.observer/filing/0001178913-25-001909.json","markdown":"https://secwatch.observer/filing/0001178913-25-001909.md","text":"https://secwatch.observer/filing/0001178913-25-001909.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/2022416/000117891325001909/0001178913-25-001909-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/2022416/000117891325001909/zk2533232.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-20T22:59:36.330205+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}